Josh Seidenfeld

Cooley advised Arsenal Biosciences (ArsenalBio), a clinical-stage programmable cell therapy company focused on engineering advanced chimeric antigen receptor T-cell (CAR-T) therapies for solid tumors, on the close of its oversubscribed $325 million Series C financing round.

Cooley advised DEFCON AI, an insights company that’s building a next-generation modeling, simulation and analysis tool set for the modern military environment, on its $44 million in Seed financing.

Cooley advised Abnormal Security, the leader in AI-native human behavior security, on its $250 million Series D financing at a $5.1 billion valuation.

Cooley advised Heartbeat Health, one of the top cardiovascular care companies in the US, on the close of its Series C financing led by Cressey & Company, a private investment firm focused on building leading healthcare services and information technology businesses.

Cooley advised Clay, a company that helps go-to-market teams up-level their data enrichment and automate personalized outreach, on its $62 million Series B financing, valuing Clay at $500 million.